Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech company developing first-in-class anti-Claudin-1 antibodies and ADCs for cancer and fibrosis. Its pipeline includes oncology candidates such as ALE.P02/ALE.P03 and the fibrosis program Lixudebart (ALE.F02).
Company facts
- Founded
- 2019
- Employees
- 67
- Headquarters
- Switzerland
- CEO
- Mark Pruzanski
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alent…
Open positions
Sr. Director, Clinical Development Oncology
About this position The Senior Director, Clinical Development is responsible for providing medical leadership and strategic input across the clinical development programs of the company. Reporting to the Vice…